Case Report: Probable blinatumomab-associated lung injury in a pediatric patient with B-ALL
- 1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Abstract
Blinatumomab is a bispecific T Cell engager targeting CD3 and CD19. Initially approved for relapsed/refractory B Cell acute lymphoblastic leukemia (B-ALL), it was later extended to first-line B-ALL therapy. Despite its high efficacy, blinatumomab carries risks of adverse effects, including cytokine release syndrome and neurotoxicity. Blinatumomab-associated lung injury is exceptionally rare. We report a pediatric B-ALL patient who developed drug-induced lung injury following induction chemotherapy, with recurrence of lung injury after blinatumomab administration. The patient presented with dyspnea, hypoxemia, and radiographic findings suggestive of interstitial lung injury. After excluding infectious and other non-infectious etiologies, we considered blinatumomab-associated lung injury as the most likely diagnosis. Symptoms improved markedly following corticosteroid therapy. Clinicians should be alert to blinatumomab-associated lung injury, achieve early recognition and administer glucocorticoid intervention. A dose-escalation strategy facilitates successful rechallenge.
Related
- Probable Rapid Eye Movement Sleep Behavior Disorder Associated With Escitalopram in a Patient With Schizoaffective Disorder: A Case Report.
- Temporal association between adjunctive repetitive transcranial magnetic stimulation and seizure reduction in a pediatric patient with DNM1L-associated EMPF1: a case report
- Severe Hypercalcemia and Acute Kidney Injury in a Patient with Probable IgG4-Related Disease and Cholestatic Liver Injury: A Case Report
- Real-world efficacy and safety of blinatumomab across three clinical settings in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective cohort study
- SEVERE HEPATOTOXICITY AND ACUTE PANCREATITIS ASSOCIATED WITH THE USE OF BLINATUMOMAB IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA
BibTeX
@article{feng2026case,
title = {{Case Report: Probable blinatumomab-associated lung injury in a pediatric patient with B-ALL}},
author = {Xingxing Feng and Tiantian Yin and Juan Han and Fen Zhou},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1973818},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1973818/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Probable blinatumomab-associated lung injury in a pediatric patient with B-ALL
AU - Xingxing Feng
AU - Tiantian Yin
AU - Juan Han
AU - Fen Zhou
PY - 2026
DA - 2026/10/21
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1973818
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1973818/full
AB - Blinatumomab is a bispecific T Cell engager targeting CD3 and CD19. Initially approved for relapsed/refractory B Cell acute lymphoblastic leukemia (B-ALL), it was later extended to first-line B-ALL therapy. Despite its high efficacy, blinatumomab carries risks of adverse effects, including cytokine release syndrome and neurotoxicity. Blinatumomab-associated lung injury is exceptionally rare. We report a pediatric B-ALL patient who developed drug-induced lung injury following induction chemotherapy, with recurrence of lung injury after blinatumomab administration. The patient presented with dyspnea, hypoxemia, and radiographic findings suggestive of interstitial lung injury. After excluding infectious and other non-infectious etiologies, we considered blinatumomab-associated lung injury as the most likely diagnosis. Symptoms improved markedly following corticosteroid therapy. Clinicians should be alert to blinatumomab-associated lung injury, achieve early recognition and administer glucocorticoid intervention. A dose-escalation strategy facilitates successful rechallenge.
SN - 1663-9812
ER -